Foolish Preview: Vertex Earnings

By Dave Williamson – Jan 29, 2013 at 3:21PM

NASDAQ: VRTX

Vertex Pharmaceuticals

Market Cap

$113B

Today's Change

(-1.65%) -$7.39

Current Price

$441.01

Price as of June 20, 2025, 3:58 p.m. ET

Taking a look at the biotech's soon-to-be-reported 4th quarter.

In this video, Motley Fool health care analyst David Williamson discusses what investors should look for in Vertex's upcoming earnings report and what the biotech has in store for 2013, including a collaboration with Johnson & Johnson.

David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid.

The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services